Medeze Group PCL (BKK:MEDEZE)
Thailand · Delayed Price · Currency is THB 6.70
-0.25 (-3.60%)
At close: Aug 10, 2026
Medeze Group PCL Financials Overview
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 735.8 | 776.41 | 873.87 | 707.37 | 611.98 | 464.29 |
Revenue Growth | -18.67% | -11.15% | 23.54% | 15.59% | 31.81% | 14.01% |
Gross Profit Gross Profit Growth | 544.64 | 580.08 | 692.93 | 555.78 | 483.33 | 338.24 |
Operating Income Operating Income Growth | 188.89 | 219.09 | 363.74 | 304.36 | 265.4 | 168.87 |
Net Income Net Income Growth | 156.12 | 196.38 | 338.74 | 239.57 | 150.71 | 123.94 |
Earnings Per Share EPS Growth | 0.15 | 0.18 | 0.39 | 0.44 | 0.33 | 0.31 |
EPS Growth | -61.68% | -53.20% | -10.19% | 30.61% | 9.76% | 16.39% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Stem Cells Sample Collection, Sorting and Cultivation - Adipose Tissue Stem Cells Sample Collection, Sorting and Cultivation - Adipose Tissue Growth | 127.66 | 130.01 | 144.97 | 133.51 | 106.36 | 75.08 |
Other Services Other Services Growth | 96.84 | 97.26 | 46.39 | 7.44 | 5.98 | 11 |
Stem Cells Sample Collection, Sorting and Cultivation - Hair Follicle Stem Cells Sample Collection, Sorting and Cultivation - Hair Follicle Growth | 14.11 | 13.57 | 10.56 | 7.12 | - | - |
Stem Cells Sample Collection, Sorting and Cultivation - Placenta Stem Cells Sample Collection, Sorting and Cultivation - Placenta Growth | 329.62 | 363.4 | 441.53 | 374.96 | 321.88 | 195.62 |
Sales of Products Sales of Products Growth | 6.08 | 7.37 | 7.67 | 9.49 | 3.88 | - |
Natural Killer Cells - Testing Services Natural Killer Cells - Testing Services Growth | 115.32 | 116.88 | 134.4 | 121.57 | 105.91 | 115.3 |
Adjustments and Eliminations Adjustments and Eliminations Growth | -44.41 | -43.74 | -42.79 | -14.58 | -7.65 | -10.85 |
Stem Cells Sample Collection, Sorting and Cultivation - Cord Blood Stem Cells Sample Collection, Sorting and Cultivation - Cord Blood Growth | 56.67 | 58.9 | 86.49 | 62.31 | 59.33 | 57.74 |
Unallocated Other Income Unallocated Other Income Growth | 33.92 | 32.76 | 44.66 | 5.56 | 16.28 | - |
Total Total Growth | 735.8 | 776.41 | 873.87 | 707.37 | 611.98 | 443.89 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,691 | 1,674 | 2,097 | 193.47 | 447.45 | 399.75 |
Total Debt Total Debt Growth | 17.95 | 19.78 | 24.61 | 10.01 | 13.41 | 109.66 |
Net Cash (Debt) Net Cash Growth | 1,673 | 1,655 | 2,072 | 183.47 | 434.04 | 290.09 |
Net Cash Growth | -22.81% | -20.14% | 1029.40% | -57.73% | 49.62% | 45.79% |
Net Cash Per Share Net Cash Per Share Growth | 1.57 | 1.55 | 2.40 | 0.34 | 0.96 | 0.71 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 202.5 | 167.23 | 326.84 | 347.9 | 314.14 | 158.09 |
Capital Expenditures CapEx Growth | -140.66 | -172.14 | -294.21 | -51.1 | -54.9 | - |
Free Cash Flow Free Cash Flow Growth | 61.84 | -4.9 | 32.63 | 296.8 | 259.24 | 158.09 |
Free Cash Flow Growth | - | - | -89.00% | 14.49% | 63.99% | 75.60% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 74.02% | 74.71% | 79.30% | 78.57% | 78.98% | 72.85% |
Operating Margin | 25.67% | 28.22% | 41.62% | 43.03% | 43.37% | 36.37% |
Pretax Margin | 23.46% | 29.48% | 42.19% | 41.69% | 28.76% | 31.35% |
Profit Margin | 21.22% | 25.29% | 38.76% | 33.87% | 24.63% | 26.70% |
FCF Margin | 8.40% | -0.63% | 3.73% | 41.96% | 42.36% | 34.05% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.160 | 0.160 | 0.160 | 0.600 | - | 0.100 |
Dividend Per Share Growth | 0% | 0% | -73.33% | - | - | 0% |
Dividend Yield | 2.30% | 2.55% | 1.86% | - | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 45.84 | 34.53 | 28.06 | - | - | - |
Forward PE | 28.51 | 16.55 | 23.81 | - | - | - |
P/FCF Ratio | 115.71 | - | 291.27 | - | - | - |
PS Ratio | 9.72 | 8.74 | 10.88 | - | - | - |